Purpose: In the placebo-controlled Phase III TELE-STAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and ≥4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4.9] kg/m 2 ) received placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg 3 times per day (TID) in addition to somatostatin analogue therapy. Weight loss is associated with uncontrolled carcinoid syndrome and may be associated with reduced survival.
ABSTRACT
Purpose: In the placebo-controlled Phase III TELE-STAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and ≥4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4.9] kg/m 2 ) received placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg 3 times per day (TID) in addition to somatostatin analogue therapy. Weight loss is associated with uncontrolled carcinoid syndrome and may be associated with reduced survival.
Methods: Assessment of the occurrence of weight change ≥3% at week 12 was prespecified in the statistical analysis plan.
Findings: In 120 patients with weight data available, weight gain ≥3% was observed in 2 of 39 patients (5.1%) taking placebo TID, 7 of 41 (17.1%) taking telotristat ethyl 250 mg TID, and 13 of 40 (32.5%) taking telotristat ethyl 500 mg TID (P ¼ 0.0017) at week 12. Weight loss ≥3% was observed in 5 of 39 patients (12.8%) taking placebo TID, 4 of 41 (9.8%) taking telotristat ethyl 250 mg TID, and 6 of 40 (15.0%) taking telotristat ethyl 500 mg TID (P ¼ 0.77). Biochemical and metabolic parameters of serum albumin and cholesterol significantly increased (P ¼ 0.02 and P ¼ 0.001, respectively) in patients gaining weight and decreased in patients who lost weight, suggesting an improvement in overall nutritional status.
Implications: Up to 32.5% of patients treated with telotristat ethyl experienced significant, dose-dependent weight gain, associated with reduced diarrhea severity and improved biochemical and metabolic
INTRODUCTION
Telotristat ethyl is used to treat patients with neuroendocrine tumors (NETs) with carcinoid syndrome not adequately controlled by somatostatin analogs (SSAs). 1 Telotristat ethyl is an inhibitor of tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis that converts tryptophan to 5-hydroxytryptophan, which is subsequently converted to serotonin. Treatment with telotristat ethyl significantly reduces both urinary 5-hydroxyindole acetic acid (u5-HIAA) concentrations and bowel movement (BM) frequency compared with placebo. [1] [2] [3] Telotristat ethyl, in combination with SSA therapy, was recently approved for adults in the United States and Europe for the treatment of carcinoid syndrome diarrhea inadequately controlled by SSAs. 4, 5 Generally, weight loss is a manifestation of advanced malignancy and is evident in patients with carcinoid syndrome, who may experience profound diarrhea. Incidence of weight gain was added as an exploratory analysis in the TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) study to determine the effects of telotristat ethyl on weight. We report dose-dependent effects of treatment with telotristat ethyl on changes in weight, metabolic parameters, and patient-reported outcomes during the 12-week double-blind treatment period of the Phase III TELESTAR clinical trial.
PATIENTS AND METHODS Patients
The TELESTAR study cohort has been described in detail previously. 1 Eligible patients were at least 18 years of age, had a histopathologically confirmed diagnosis of a metastatic NET, had a documented history of carcinoid syndrome with at least 4 BMs per day, and were receiving treatment with long-acting SSAs for ≥3 months before enrollment. Detailed inclusion and exclusion criteria have been published previously. 1 
Study Design and Treatment
Eligible patients entered a screening period of 3 or 4 weeks, depending on their SSA dose schedule, to establish baseline symptoms. Patients were randomly assigned 1:1:1 to orally receive placebo 3 times per day (TID), telotristat ethyl 250 mg TID, or telotristat ethyl 500 mg TID for the 12-week double-blind treatment period. Treatment with SSAs was continued. Rescue use of short-acting octreotide and antidiarrheal agents was unrestricted, but there was no significant difference in use among the treatment arms.
1 Downward dose adjustment of telotristat ethyl was not allowed during the double-blind treatment period. The study was approved by the respective institutional review boards or ethics committees at the participating centers. All patients gave written informed consent. The study complied with the ethical principles of the Declaration of Helsinki and with Good Clinical Practice guidelines. 6 The study drug dosage form consisted of whitecoated, debossed oval tablets that contained 250 mg of telotristat ethyl or matching inactive placebo of microcrystalline cellulose. There was no taste reported for the tablets. During the dose-escalation phases, the assigned study drug was provided in 8-day blister packs that contained 6 columns and 8 rows for a total of 48 tablets. After the dose-escalation phase, patients received their assigned study drug in 100-mL highdensity polyethylene bottles with child-resistant polypropylene screwcaps and heat-induction seal liners. There was no official assessment of the success of matching performed.
Prior medical histories (before enrollment) were reviewed relating to weight gain, weight loss, and nutritional status by searching for relevant conditions among the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes of Gastrointestinal Disorders, General and Nutritional Disorders, and Metabolic Parameters. The potential associations of weight change with BM frequency reduction and changes in u5-HIAA concentrations were examined. Patient-reported outcomes were examined with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) for items that describe a global assessment or aspects that relate directly or indirectly to gastrointestinal function. Selected metabolic parameters (serum cholesterol, triglycerides, and albumin) and serum creatinine were compared among patients in the categories of weight gain, stable weight, and weight loss.
The incidences of serious adverse events, discontinuation attributable to adverse events, and death were examined, along with the types of adverse events experienced, among patients in the categories of weight gain, stable weight, and weight loss. In addition, possible adverse events of the treatment relating to edema, weight loss, and malnutrition were examined.
Statistical Analysis
Statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina). Results are presented as mean (SD). A 2-tailed P o 0.05 was considered statistically significant. Assessment of the incidence of weight change of ≥3% at week 12 was prespecified in the TELESTAR statistical analysis plan. Posthoc analyses included Kruskal-Wallis tests and Fisher exact tests to investigate differences among groups. CochranArmitage tests were applied to investigate for trends in the incidence of weight gain in the placebo, telotristat ethyl 250 mg TID, and telotristat ethyl 500 mg TID treatment groups; ANOVA was applied to test for changes in metabolic markers among patients with weight gain, stable weight, and weight loss. A threshold of 3% weight change was assumed to be clinically relevant and prespecified for the analyses based on the assumption that this degree of weight change would be achievable during a 12-week treatment period and was considered unlikely to be caused by chance alone.
RESULTS

Baseline Characteristics
Of 135 randomly assigned patients in the TELE-STAR trial, 120 had available data for inclusion in this analysis. A total of 15 patients did not have their weight measured at baseline (4 patients) or week 12 (13 patients) (2 patients did not have their weight measured at either time point), so their changes from baseline could not be calculated (Supplemental Fig. 1 ). Of the 13 patients who had no weight measurement at week 12, 9 patients discontinued from the study before week 12, 2 patients completed but did not have their weight measured at week 12, and 2 patients did not have their weight measured at baseline or week 12. During the double-blind treatment period, 5 patients died (3 in the placebo group and 1 each in the telotristat ethyl 250 mg and 500 mg TID groups). These patients had no data available at the week 12 follow-up visit and therefore could not be categorized with regard to weight change. Some of the patients who discontinued the study because of adverse events could be categorized: although the adverse event had its onset during the double-blind treatment period, the discontinuation occurred after the week 12 weight data were collected.
Baseline characteristics of the patients are presented in Table I and Supplemental Table I . For this analysis, patients were separated into 3 groups, according to occurrence of alteration of their weight during the 12-week double-blind treatment period as those with ≥3% weight gain, those maintaining stable weight, or those experiencing ≥3% weight loss. Baseline characteristics were established on day 1 of the double-blind treatment period, the same day as the first dose of study drug. Baseline u5-HIAA was established during the screening or run-in period, at least 2 weeks before day 1.
Medical History
All patients had a history of a histologically confirmed, well-differentiated metastatic NETs and a clinical diagnosis of carcinoid syndrome. Patients in the TELESTAR study had been diagnosed with metastatic NETs a mean of 7 years before randomization. Additional histories relevant to nutritional status are given in Table II .
Duration of Treatment
The mean duration of treatment exposure during the double-blind treatment period was 12.1, 11.7, and 10.8 weeks among patients with weight gain, stable weight, and weight loss, respectively.
Weight Changes
Weight gain ≥3% at week 12 was observed in 2 of 39 patients (5.1%) taking placebo, 7 of 41 patients (17.1%) taking telotristat ethyl 250 mg TID, and 13 of 40 patients (32.5%) taking telotristat ethyl 500 mg TID. The occurrence of weight gain across groups was significantly different among the 3 groups (P ¼ 0.0017) ( Figure 1A ). There was no significant difference among the treatment arms for the occurrence of weight loss ≥3% (P ¼ 0.77) ( Figure 1B) . The mean weight gain was approximately 5% in those classified as having ≥3% weight gain, whereas those with weight loss experienced a substantial mean loss of 7%. There was a small treatment effect observed in mean weight change ( Figure 2 ). Table III summarizes changes in weight relative to baseline after the 12-week doubleblind treatment period.
Changes in BM Frequencies
The mean baseline BM frequency was 5.8 BMs per day and was comparable among the groups (weight gainers, 6.7 BMs per day; stable weight, 5.5 BMs per day; weight losers, 5.3 BMs per day; P ¼ 0.47). Among patients with a weight gain occurrence, changes in BM frequency at week 12 were -1.2, -1.3, and -2.5 for those treated with placebo (n ¼ 2), telotristat ethyl 250 mg TID (n ¼ 7), and telotristat ethyl 500 mg TID (n ¼ 13), respectively. Overall, patients with weight gain (including those in the placebo, telotristat ethyl 250 mg TID, and telotristat ethyl 500 mg TID groups) experienced a reduction in BM frequency at week 12 of -2.0 BMs per day. Reductions at week 12 were -1.3 and -1.7 BMs per day for those with stable weight and those with ≥3% weight loss, respectively.
Changes in u5-HIAA Concentrations
Baseline values of u5-HIAA were 142, 45, and 90 mg per 24 hours among patients with occurrences of weight gain, stable weight, and weight loss, respectively, and they were highest in the group of patients who were weight gainers (P o 0.001). The largest reductions in u5-HIAA were observed in the patients who experienced weight gain, with an observed 57% decrease in u5-HIAA levels, although some reductions in u5-HIAA were observed in patients with stable weight (12%) and weight loss (39%) (P ¼ 0.009). Mean absolute changes in u5-HIAA among patients with weight gain, stable weight, and weight loss at week 12 were -90, -11, and -36 mg per 24 hours, respectively.
Changes in Selected Metabolic Parameters Related to Nutritional Status
Changes in metabolic parameters of nutritional status and in serum creatinine concentrations as a marker for dehydration or rehydration or possible development of edema are presented in Table IV . Results are presented as changes relative to the baseline and are separated by patients who had experienced ≥3% weight gain, who maintained their weight, or who experienced ≥3% weight loss during the 12-week study period, as well as by treatment arm.
Patient-reported Outcomes
For patients who had experienced weight gain during the 12-week study period, more favorable patient-reported outcomes were identified as evidenced by numerically higher scores in the EORTC QLQ-C30 items that related to global status or quality of life and physical function and numerically lower scores for EORTC QLQ-C30 items that related to gastrointestinal function. In addition, there was a large numerical difference in Global Health Score for patients who had lost weight compared with those with stable weight or weight gain, and there was a statistically significant difference between the 3 weight change groups. The scores presented in Table V reflect mean changes from baseline for the double-blind treatment period. Results using the EORTC QLQ-C30 in TELESTAR were generally similar among the treatment groups, with the most prominent difference being an improvement in the diarrhea subscale with telotristat ethyl compared with placebo. The full results were previously reported. 1 A summary of adverse events in relation to the occurrence of weight gain, weight loss, and nutritional status is presented in Supplemental Tables II and III. The incidence of peripheral edema reported during double-blind treatment was consistent with its reporting in medical history, before treatment with placebo, telotristat ethyl 250 mg TID, or telotristat ethyl 500 mg TID. There was a higher incidence in the weight gain group (18.2%) than in the weight loss group (6.7%) during treatment (Supplemental Table III) , and it was more common in the weight gain group (27.3%) than the weight loss group (6.7%) in the medical history (Table II) .
DISCUSSION
We provide the first report of the effects of treatment with telotristat ethyl on occurrences of changes in weight in the Phase III, multicenter, double-blind, placebo-controlled TELESTAR clinical trial in 120 patients with NETs and carcinoid syndrome. The use of telotristat ethyl in this trial was associated with a significant and clinically meaningful dose-dependent increase in the occurrence of weight increase after 12 weeks. Furthermore, patients with weight gain had not only evidence of improved carcinoid syndrome control (reduced BM frequency and reduced u5-HIAA levels) but also significant improvement in parameters of nutritional status associated with positive changes in patient-reported outcomes compared with patients with stable weight or who had experienced weight loss. Weight loss and malnutrition in patients with malignant tumors are linked to major negative outcomes, including excess mortality and morbidity and higher treatment costs. [7] [8] [9] Although patients with NETs typically do not present with major weight loss or acute illness before reaching terminal stages with extensive metastatic involvement or carcinoid heart disease, 10 recent studies have found that some degree of malnutrition (mainly based on assessment of body mass index o20 kg/m 2 ) is common in patients with NETs, with reported prevalence between 14% and 25%. 10, 11 Malnutrition in patients with NETs and carcinoid syndrome could be present for distinct reasons (in addition to the cachexia that might be expected in patients with cancer), which include chronic loose stools, osmotic diarrhea, and excess secretion of serotonin precursors that stimulate gut transit and small-bowel motility in functioning tumors. 10, [12] [13] [14] Treatment with telotristat ethyl improves BM frequency and reduces u5-HIAA levels. [1] [2] [3] In our study, u5-HIAA levels decreased by 57% in the group of patients who experienced weight gain, and this decrease was significantly more pronounced when compared with those observed in the groups of patients who had experienced stable weight or weight loss. It is therefore feasible that the dose-dependent effect of treatment with telotristat ethyl on weight gain observed here in patients with carcinoid syndrome might indeed be explained by reduced small-bowel motility and improved nutrient absorbance via telotristat ethyl-related reductions of u5-HIAA levels. Although weight loss in patients with carcinoid syndrome could also be, at least in part, related to pancreatic masses, tumor infiltration of the mesentery in midgut NETs, prior abdominal surgery, or treatment with SSAs, 10 treatment with telotristat ethyl would not be expected to influence these factors. In the group of patients who had experienced weight loss, treatment with telotristat ethyl also appeared to improve diarrhea, although to a lesser extent, but it Clinical Therapeutics did not result in an improvement of parameters of nutrition status. The absence of a significant difference between the treatment arms in patients who experienced weight loss may suggest reduced efficacy of telotristat ethyl in patients with more rapid disease progression. A possible explanation could be that the control of carcinoid syndrome may help patients gain weight if they have stable disease, whereas poor patient outcomes and adverse events associated with weight loss could be linked to rapid tumor progression.
Our finding of dose-dependent significant increases of serum cholesterol and albumin concentrations in the telotristat ethyl treatment groups, together with unchanged serum creatinine clearance, would suggest that the observed occurrences of weight gain in the telotristat ethyl treatment groups cannot be solely related to rehydration, or possibly development of edema, and appear to represent some true metabolic improvement. Although the involved mechanisms remain to be defined, it appears that patients who had weight gain experienced fewer adverse events in this study; notably, malnutrition and weight loss are associated with negative outcomes. [9] [10] [11] 14 There was no clear pattern of increased frequency of edema or cardiac conditions to explain the observed weight gain in this group. Patients who experienced weight gain also had improvements in patient-reported outcomes and fewer serious adverse events compared with those with stable weight or weight loss, further supporting that the weight gain observed in the telotristat ethyl treatment groups was clinically beneficial.
The strengths of this study include the design as a randomized, double-blind, placebo-controlled trial and the large multicenter cohort of well-characterized patients with NETs and carcinoid syndrome. ⁎ Results are presented separately for 120 patients with neuroendocrine tumors and carcinoid syndrome who had experienced ≥3% weight gain, who maintained their weight, or who experienced ≥3% weight loss during the 12-week double-blind treatment period.
† P values refer to Kruskal-Wallis test of group differences (≥3% weight gain, stable weight, or ≥3% weight loss groups) and are descriptive.
Limitations include the lack of availability of additional markers to assess the nutritional status, such as food diaries, measures of sarcopenia, or biomarkers of heart failure, such as serum brain natriuretic peptide. Furthermore, although investigation of the incidence of weight gain was prespecified and added as an additional exploratory analysis to the statistical analysis plan of TELESTAR before study completion based on the suggestion of regulatory authorities to examine the nutritional status of our patients, it was not a registered secondary outcome measure of this study. Further studies are needed to better understand the potential mechanisms behind the observed dosedependent occurrence of weight gain on treatment with telotristat ethyl and whether telotristat ethylinduced weight gain has long-term implications for maintaining the health of patients with carcinoid syndrome. The observation that increased weight appears to be a protective factor for survival in patients with NETs is promising in this context. 15 In conclusion, among patients with NETs and carcinoid syndrome, the use of telotristat ethyl in a Phase III clinical trial was associated with a significant increase in the occurrence of weight gain. Patients with weight gain had evidence of carcinoid syndrome control, some positive changes in patient-reported outcomes, improvements in selected parameters of nutritional status, and fewer serious adverse events than patients with stable weight or weight loss. More research is warranted to understand the mechanisms and potential long-term effect of these changes. 
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